Business model and IPR
For our customers and partners we custom engineer ”InGell” injectable drug depot systems towards the optimal release profile of the active pharmaceutical ingredient in play.
We have a strong and acknowledged Patent portfolio consisting of a series of granted and pending composition-of-matter claims, covering most modern day applications for localized and sustained delivery and imaging using injectable depots.
Our business model is a combination of dedicated development agreements, licensing agreements and supply agreements.
Collaborations are always custom-made but generally follow the path of:
1. Feasilibility studies;
2. Basic agreement on licensing conditions;
3. Full development program;
4. Full agreement on licensing conditions;
5. Supply chain securement.